EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections



Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections



Vaccine 23(23): 3033-3042



A safe and effective pan-filovirus vaccine is highly desirable since the filoviruses Ebola virus (EBOV) and Marburg virus (MARV) cause highly lethal disease typified by unimpeded viral replication and severe hemorrhagic fever. Previously, we showed that expression of the homologous glycoprotein (GP) and matrix protein VP40 from a single filovirus, either EBOV or MARV, resulted in formation of wild-type virus-like particles (VLPs) in mammalian cells.

(PDF emailed within 0-6 h: $19.90)

Accession: 004383747

Download citation: RISBibTeXText

PMID: 15811650

DOI: 10.1016/j.vaccine.2004.11.070



Related references

A multiagent filovirus DNA vaccine delivered by intramuscular electroporation completely protects mice from ebola and Marburg virus challenge. Human Vaccines & Immunotherapeutics 8(11): 1703-1706, 2013

Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clinical and Vaccine Immunology 15(3): 460-467, 2008

Computer simulations of proteolysis of Marburg and Ebola-Zaire filovirus coded proteins to generate nonapeptides with motifs of known HLA class I haplotypes and detection of antigenic domains in the viral glycoproteins. Virus Genes. 13(3): 189-201, 1996

Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges. Human Vaccines & Immunotherapeutics 11(8): 1991-2004, 2016

Identity and validity of conserved B cell epitopes of filovirus glycoprotein: towards rapid diagnostic testing for Ebola and possibly Marburg virus disease. Bmc Infectious Diseases 18(1): 498-498, 2018

Filovirus ebola et Marburg. Annales de L'institut Pasteur / Actualit├ęs 8(3): 207-222, 1997

Ebola virus disease and Marburg disease in pregnancy: a review and management considerations for filovirus infection. Obstetrics and Gynecology 125(6): 1293-1298, 2015

Interaction of Tsg101 with Marburg virus VP40 depends on the PPPY motif, but not the PT/SAP motif as in the case of Ebola virus, and Tsg101 plays a critical role in the budding of Marburg virus-like particles induced by VP40, NP, and GP. Journal of Virology 81(9): 4895-4899, 2007

Biophysical characterization and conformational stability of Ebola and Marburg virus-like particles. Journal of Pharmaceutical Sciences 100(12): 5156-5173, 2012

Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. Journal of Virology 83(14): 7296-7304, 2009

Conserved motifs within Ebola and Marburg virus VP40 proteins are important for stability, localization, and subsequent budding of virus-like particles. Journal of Virology 84(5): 2294-2303, 2010

Animal models for Ebola and Marburg virus infections. Frontiers in Microbiology 4: 267-267, 2013

Ebola and Marburg virus-like particles activate human myeloid dendritic cells. Virology 326(2): 280-287, 2004

Host and Viral Proteins Modulating Ebola and Marburg Virus Egress. Viruses 11(1), 2019

Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. Journal of Infectious Diseases 204 Suppl 3: S1075-S1081, 2011